Regeneron (REGN) Reports Updates on Phase 3 Libtayo (cemiplimab) Development Program in Advanced NSCLC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Regeneron Pharma (REGN) PT Raised to $352 at BMO Capital
November 5, 2019 3:43 PM ESTBMO Capital analyst Matthew Luchini raised the price target on Regeneron Pharma (NASDAQ: REGN) to $352.00 (from $344.00) while maintaining a Market Perform rating.
The analyst commented, "Regeneron reported a top- and bottom-line beat reflecting a combination of Eylea, Dupixent and another profitable quarter for the... More
Regeneron (REGN) Tops Q3 EPS by 31c, Offers FY Guidance
November 5, 2019 6:32 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $6.67, $0.31 better than the analyst estimate of $6.36. Revenue for the quarter came in at $2.05 billion versus the consensus estimate of $1.99 billion.
2019 Financial... More
